• Canagliflozin: Reading SGLT2 Data Beyond mTOR

  2026-09-02

  Canagliflozin hemihydrate is a useful probe for renal glucose reabsorption inhibition and glucose metabolism research. This article explains how a 2025 drug-sensitized yeast study can sharpen assay selection, control interpretation, and pathway-level conclusions without confusing SGLT2 biology with mTOR inhibition.

• Antimycin A4: Designing Dual-Mechanism Assays

  2026-09-01

  Antimycin A4 is an ATP-citrate lyase inhibitor with a second mitochondrial respiratory-chain activity. This guide presents a mechanism-aware strategy for separating lipid-biosynthesis effects from respiratory stress while using orthogonal controls, time courses, and assay-specific interpretation.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-09-01

  Hydroxychloroquine Sulfate provides an aqueous-compatible research reagent for investigating autophagy pathway modulation and TLR7/9-associated immune signaling in cellular and animal models. It is suited to autoimmune disease research workflows requiring water-based preparation, but not to protocols dependent on DMSO or ethanol solubility or long-term solution storage.

• Brassinolide: From Plant Signal to Translational Probe

  2026-08-31

  Brassinolide, also encountered in research contexts as 24-Epibrassinolide, offers a distinctive bridge between plant developmental biology and preclinical cancer and metabolic research. This article interprets its context-dependent biology, outlines validation workflows, and defines the evidence standards needed to move from compelling assay signals toward translational confidence.

• N-Glycosylation, MerTK, and HCC Tumor Growth

  2026-08-31

  The reference study identifies MerTK N-glycosylation as a post-translational mechanism that stabilizes this receptor and supports hepatocellular carcinoma growth. Its integrated cell, metabolic, tumor, and tissue analyses connect MerTK glycosylation with reactive oxygen species control, oxidative phosphorylation, stress survival, and prognosis, while suggesting—but not yet proving—N-glycosylation inhibition as a therapeutic strategy.

• VX-661: Interpreting F508del CFTR Rescue

  2026-08-30

  Explore how VX-661, a F508del CFTR corrector, restores CFTR trafficking and how calnexin, assay timing, and orthogonal readouts shape interpretation in cystic fibrosis research.

• Anagliptin Vasorelaxation in Rabbit Aorta

  2026-08-29

  A 2025 Acta Diabetologica study identifies a previously undercharacterized vascular action of Anagliptin: dose-dependent relaxation of phenylephrine-contracted rabbit aortic rings involving voltage-dependent K+ channels and the SERCA pump. Pharmacological controls indicate that the response is independent of endothelium, cAMP/PKA and cGMP/PKG signaling, and several other vascular K+ channel classes, providing a focused framework for vasorelaxant mechanism research.

• Anti-Diabetic Drugs and Fracture Risk: Network Evidence

  2026-08-28

  This systematic review and network meta-analysis integrated randomized evidence on fracture outcomes across multiple anti-diabetic drug classes and individual agents in type 2 diabetes. Its main contribution is a comparative framework showing that most treatments were not statistically different from placebo, while trelagliptin, voglibose, and albiglutide produced distinct signals that require interpretation alongside uncertainty and clinical context.

• Brassinolide: Workflows for Plant and Cell Assays

  2026-08-28

  Brassinolide supports two distinct research workflows: benchmarked plant growth bioassays and mechanistic apoptosis studies in PC-3 prostate cancer cells. This guide covers formulation, assay design, comparative interpretation, and troubleshooting while separating established evidence from practical starting conditions.

• Ertugliflozin: From Transport Assay to Outcomes

  2026-08-27

  Ertugliflozin and PF-04971729 offer a precise framework for studying renal glucose reabsorption inhibition. This article connects transport biology, assay design, and cardiovascular outcome interpretation while defining the limits of translational claims.

• PEGylated Iron Oxide Nanoparticles in the Liver

  2026-08-27

  This ACS Nano study separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic distribution using 99mTc tracing, SPECT/CT, and primary liver-cell assays. Its finding that hepatocytes and stellate cells can contribute substantially to uptake, while 2K PEG minimizes hepatic accumulation, provides a more cell-resolved framework for nanomedicine design.

• Elobixibat Hydrate: IBAT Assay Workflows

  2026-08-26

  Elobixibat hydrate enables target-focused studies of ileal bile acid transport, intestinal motility, and downstream TGR5–GLP-1 signaling. This workflow guide connects formulation, concentration-response testing, translational endpoints, and troubleshooting for constipation, colonoscopy preparation, and metabolic research.

• Elobixibat Hydrate: From IBAT Biology to Assays

  2026-08-26

  Elobixibat hydrate is an ileal bile acid transporter inhibitor whose value extends beyond laxation: it offers a mechanistically resolved way to study bile acid delivery, epithelial secretion, motility, and metabolic signaling. This guide translates the core literature into practical assay and interpretation decisions.

• ACE Inhibitor-Mediated Angioedema: Mechanisms and Care

  2026-08-25

  Montinaro and Cicardi synthesize the epidemiology, bradykinin-centered pathophysiology, risk modifiers, and treatment uncertainty surrounding ACE inhibitor-mediated angioedema. The review’s practical contribution is to distinguish this adverse reaction from histamine-driven allergy and to clarify why drug withdrawal, airway assessment, and cautious selection of alternative renin–angiotensin system therapy are central to management.

• E-4031: From hERG Blockade to 3D Arrhythmia Maps

  2026-08-25

  E-4031 is more than a potent hERG potassium channel blocker: it is a strategic perturbation tool for connecting ion-channel mechanism with tissue-level arrhythmia phenotypes. Combined with shell microelectrode arrays and cardiac organoids, it can help translational researchers move from QT interval prolongation to spatially resolved models of proarrhythmic risk.

8139 records 3/543 page Previous Next 12345 下5页 Last page